Press releases

View Press releases from

16 May, 2019

ANNUAL GENERAL MEETING 2019 IN KARO PHARMA AKTIEBOLAG

At today’s annual general meeting of Karo Pharma, the following decisions were passed. The annual general meeting resolved to adopt the income statement and balance sheet for the group and the parent company. The annual general meeting resolved that available funds, including the earnings for the year, were to be carried forward. The annual general...

Read more
16 April, 2019

NOTICE OF ANNUAL GENERAL MEETING IN KARO PHARMA AKTIEBOLAG

The shareholders of Karo Pharma Aktiebolag, reg. no. 556309-3359, are given notice of the annual general meeting to be held at 14:00 CET on 16 May 2019, at Näringslivets Hus, Storgatan 19 in Stockholm.

Read more
9 April, 2019

New date for the annual general meeting of Karo Pharma

STOCKHOLM on 9 April 2019

Read more
3 April, 2019

Christoffer Lorenzen appointed CEO of Karo Pharma; Peter Blom resigning.

The Board of Karo Pharma Aktiebolag (publ) (“Karo Pharma”) has appointed Christoffer Lorenzen as the new CEO of Karo Pharma, replacing Peter Blom. Christoffer will take on his new position on July 1, 2019. Up until this date, and effective as of today, Ulf Mattsson assumes the CEO position on an interim basis. Karo Pharma...

Read more
11 February, 2019

Karo Intressenter’s proposals ahead of the Extraordinary General Meeting in Karo Pharma on 14 February 2019

EQT VIII[1] through Karo Intressenter AB (”Karo Intressenter”) proposes, ahead of the Extraordinary General Meeting in Karo Pharma Aktiebolag (”Karo Pharma”) on 14 February 2019 that the Board Member Håkan Åström is reelected and that Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen and Åsa Riisberg are elected as new Board Members with Bo Jesper Hansen as Chairman of the Board.

Read more
2 January, 2019

STATEMENT BY THE BOARD OF DIRECTORS OF KARO PHARMA AKTIEBOLAG IN RELATION TO THE INCREASED PUBLIC OFFER FROM EQT VIII, THROUGH KARO INTRESSENTER AB

The Board of Directors of Karo Pharma Aktiebolag has concluded to unanimously recommend that the shareholders of Karo Pharma Aktiebolag accept the increased public offer made by EQT VIII, through Karo Intressenter AB.

Read more